The main active ingredient in Brimosun P is Brimonidine Tartrate. This substance acts as an α2-adrenergic receptor agonist and is primarily prescribed for treating ocular hypertension and open-angle glaucoma.
Brimosun P is utilized for the treatment, prevention, control, and improvement of various conditions and symptoms, including ocular hypertension and open-angle glaucoma. It functions by decreasing the volume of fluid within the eye, which helps to lower the pressure inside it.
The typical dosage is one drop in the affected eye two to three times daily for the duration recommended by your healthcare provider. The dosage may vary depending on the severity of the condition, individual response to treatment, potential drug interactions, and other factors. A comprehensive eye examination will determine the appropriate dosage.
Before administering the drops, make sure to wash your hands thoroughly. To apply the eye drops, tilt your head backward, then gently pull the lower eyelid down to create a pouch for the drop. After applying the drop, keep your eye closed for a short period before returning to normal activities.
Taking an excessive dose of Brimosun P can exacerbate the condition, so it's important to avoid overdosing. In the event of an overdose, seek immediate medical attention.
Individuals using Brimosun P may experience unwanted side effects such as abnormal taste, distorted vision, blurred vision, lightheadedness, eye irritation, reddening of the eye, swelling in the eye, and allergic reactions affecting the eye.